苏楠

2017-06-23

苏楠博士于2003年在北京清华大学生命科学院取得生物学学士学位,其后加入美国佛罗里达大学生化与分子生物学系Michael Kilberg教授的实验室从事博士学位研究。在研究期间,他着重于阐明诸如氨基酸类的营养分子对基因表达调控的机理,并且发现了儿童急性白血病患者对于化疗药物天冬酰胺酶产生抗药性的原理。2008年取得博士学位以后,苏楠博士移居到加利福尼亚州并加入Advanced Cell DiagnosticACD)公司担任研发科学家,帮助开发RNAscope技术。这是一项革命性的RNA原位杂交技术,它可以帮助研究者通过普通光学显微镜在细胞与组织形态中看到单个RNA分子的信号并进行定量的分析,从而成为了生物医学研发以及临床检测中一个强大而重要的工具。2012年到2017年之间,苏楠博士先后担任公司研发部的总监和高级总监并且领导开发出了一系列创新性的技术,例如全自动以及多基因检测的RNAscope方法。2016年,ACDBio-Techne集团以3.25亿美元的价格收购。2017年初,苏楠博士共同创建了Clover Biomedical Systems公司,提供高质量的研发与诊断对照样品,并且提供全流程的组织病理学服务。

Dr. Nathan (Nan) Su received his B.S. degree from School of Life Sciences at Tsinghua University in 2003. He then joined Dr. Michael Kilberg’s laboratory at University of Florida, Department of Biochemistry and Molecular Biology, to pursue his Ph.D., during which period, he studied the molecular mechanisms of gene expression regulation by nutrient molecules, such as amino acids. He also elucidated the mechanism of resistance to the chemotherapy drug, Asparaginase, in patients with Childhood Acute Lymphoblast Leukemia. After obataining his Ph.D degree in 2008, Dr. Su joined Advanced Cell Diagnostics, Inc (ACD), California, as a Scientist and helped to develop the RNAscope technology, which allows visualization of single RNA molecules at single cell level. This revolutionary RNA in situ hybridization technology allows quantitative analysis of gene expression in the morphological context of cells and tissue specimens and provides a powerful tool for research and clinical diagnostics. From 2012 to 2017, Dr. Su served as Director and Sr. Director of R&D and led the development of a series of novel technologies, such as fully automated and multiplex RNAscope assays. In 2016, ACD was acquired by Bio-Techne Corporation for $325 million dollars. In the beginning of 2017, Dr. Su co-founded Clover Biomedical Systems, Inc., which provides high quality control samples for research and diagnostics, as well as full workflow histopathology services.

 


上一篇:胡旭波
下一篇:陈宏武
Powered by 飞色网络